List of Excipients in Branded Drug OXYGEN HELIUM MIXTURE

« Back to Dashboard

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Aero All Gas Company	OXYGEN HELIUM MIXTURE	oxygen helium mixture	10014-009	HELIUM
AGL Inhalation Therapy Co	OXYGEN HELIUM MIXTURE 20/80	oxygen helium mixture 20/80	17575-192	HELIUM
Aero All Gas Company	OXYGEN HELIUM MIXTURE 30/70	oxygen helium mixture 30/70	10014-018	HELIUM
AGL Inhalation Therapy Co	OXYGEN HELIUM MIXTURE 30/70	oxygen helium mixture 30/70	17575-038	HELIUM
Aero All Gas Company	OXYGEN HELIUM MIXTURE 40/60	oxygen helium mixture 40/60	10014-008	HELIUM

Oxygen-Helium Mixture Excipient Strategy and Commercial Opportunities

Last updated: October 4, 2026

Oxygen-helium mixture, commonly called heliox, is a medical gas composed of oxygen and helium. Its commercial value comes from reduced gas density and lower turbulent resistance in narrowed airways, not from an excipient system. In a conventional heliox product, both oxygen and helium are active gases. The principal development variables are gas ratio, purity, container system, delivery equipment, labeling, and manufacturing controls.

The strongest commercial opportunities are in emergency respiratory support, specialty hospital supply, home-care delivery systems, and integrated gas-delivery devices. The principal barriers are limited clinical differentiation, dependence on respiratory equipment, hospital procurement economics, and the absence of a conventional small-molecule patent moat.

What is an oxygen-helium mixture and how is it used?

Heliox is a premixed gas containing helium and oxygen. Common compositions include 80% helium and 20% oxygen, 70% helium and 30% oxygen, and 60% helium and 40% oxygen.

Composition	Typical positioning	Commercial consideration
80% helium / 20% oxygen	Maximum density reduction	Oxygen concentration is close to room air and may be inadequate for hypoxemic patients
70% helium / 30% oxygen	Common clinical compromise	Balances reduced gas density with greater oxygen availability
60% helium / 40% oxygen	Higher oxygen support	Provides less density reduction than higher-helium mixtures
Patient-specific blend	Intensive-care or emergency use	Requires controlled blending, monitoring, and compatible equipment

Helium has substantially lower density than nitrogen, the principal inert gas in ordinary air. Replacing nitrogen with helium can improve flow through narrowed airways and reduce the work of breathing. Clinical use has been evaluated in upper-airway obstruction, severe asthma, bronchiolitis, croup, chronic obstructive pulmonary disease, and selected ventilatory-support settings. Clinical evidence is mixed and generally supports heliox as an adjunct rather than a replacement for definitive treatment or oxygen therapy.[1-3]

Heliox is administered through masks, hoods, noninvasive ventilation systems, high-flow systems, ventilators, or specialized delivery circuits. Its benefit depends on maintaining a sufficiently high helium fraction and using equipment that preserves the intended composition.

What is the excipient strategy for oxygen-helium mixtures?

A conventional oxygen-helium mixture has no excipient.

Both oxygen and helium have a functional purpose:

• Oxygen supports tissue oxygenation.
• Helium reduces the density of the inhaled gas and changes flow dynamics.

The formulation is therefore a binary active-gas system rather than an active ingredient combined with inactive excipients. Adding an excipient would generally create clinical, safety, regulatory, and compatibility problems.

Are stabilizers or preservatives needed?

No conventional preservative, antioxidant, buffer, surfactant, or stabilizer is required. Helium is chemically inert under ordinary storage conditions. Oxygen does not require a liquid-phase stabilizer in a compressed-gas product.

The principal quality controls are:

• Gas identity
• Oxygen concentration
• Helium concentration
• Water content
• Hydrocarbon and oil contamination
• Particulate matter
• Carbon monoxide and carbon dioxide limits, where applicable
• Cylinder pressure
• Fill accuracy
• Leak integrity
• Valve and regulator compatibility

Medical-gas manufacturing must control contamination because oxygen can accelerate combustion and react with incompatible lubricants, polymers, oils, and organic residues. Container and closure systems must be suitable for oxygen service.

Can nitrogen or another gas be used as an excipient?

Nitrogen may be present as an impurity or may be used in other gas formulations, but it is not normally an excipient in heliox. Adding nitrogen reduces the helium fraction and changes the intended aerodynamic properties. Carbon dioxide is not an appropriate routine excipient because it can affect ventilation, acid-base balance, and respiratory drive.

Water vapor is also not a formulation excipient. Excess moisture can create corrosion, freezing, microbial-control, or equipment-performance issues. The product should be specified as a dry medical gas within an established moisture limit.

What formulations are protected by oxygen-helium mixture patents?

The composition alone is unlikely to provide a durable patent strategy unless the claims cover a narrowly defined therapeutic use, delivery method, gas ratio, or device interaction.

Potential claim categories include:

Claim category	Potential subject matter	Relative commercial value
Composition	Defined oxygen and helium ranges with impurity limits	Low to moderate
Method of treatment	Use in a specified patient population or disease state	Moderate, subject to clinical evidence
Delivery protocol	Flow rate, pressure, fraction of inspired oxygen, or transition sequence	Moderate
Device	Mixer, regulator, ventilator interface, mask, or flow-control system	Moderate to high
Monitoring	Closed-loop control using oxygen, pressure, flow, or carbon-dioxide sensors	High if technically differentiated
Manufacturing	Precision blending, filling, validation, or cylinder-management process	Moderate
Packaging	Specialized cylinder, valve, cartridge, or transport system	Moderate

A broad claim covering "an oxygen-helium mixture" would face substantial validity and enforceability pressure because medical heliox compositions and respiratory uses have been publicly known for decades. The more defensible strategy is to claim a specific delivery architecture or a clinically validated protocol.

How strong is the patent estate for heliox?

The patent estate is likely stronger around delivery hardware and clinical-use methods than around the gas mixture itself.

Composition patents

Composition claims face prior-art risks from established heliox use, published medical-gas specifications, and known oxygen-helium ratios. A new composition may be patentable if it has a defined technical effect, such as improved delivery stability, lower contamination, or a measurable clinical advantage. Routine changes in oxygen concentration are unlikely to provide a strong standalone moat.

Formulation and manufacturing patents

Manufacturing claims may cover:

• Inline proportioning of oxygen and helium
• Automated blend verification
• High-accuracy filling across cylinder sizes
• Low-temperature filling controls
• Contamination prevention in oxygen service
• Blending directly at the point of care
• Digital authentication of gas composition

These claims can protect operations but may be difficult to enforce against conventional premixed-gas suppliers if the same result can be achieved through different manufacturing methods.

Device patents

Device IP is the most commercially relevant area. Opportunities include:

• Portable heliox cartridges
• Oxygen-helium concentrator systems
• Ventilator-compatible mixers
• Low-dead-space masks
• Heliox-compatible nebulizer systems
• Closed-loop oxygen adjustment
• Gas-composition sensors
• Automatic compensation for flow-meter error caused by low-density gas

A device that improves portability, reduces gas waste, or maintains a target oxygen fraction has greater commercial differentiation than a standard cylinder of premixed gas.

What is the FDA regulatory status of oxygen-helium mixtures?

In the United States, oxygen and other medical gases are regulated by the FDA as drugs when manufactured, packaged, or labeled for medical use. FDA’s medical-gas framework addresses production, current good manufacturing practice, labeling, registration, and listing requirements.[4]

A heliox product may require regulatory analysis based on:

• Whether the product is manufactured as a finished medical gas
• The intended indication and labeling
• The gas ratio and specifications
• Whether it is premixed or blended at the point of care
• The delivery device used with the gas
• Whether the product is compounded or commercially manufactured
• The jurisdiction and distribution model

The regulatory pathway is materially different from that for a conventional tablet or injectable. Product quality, gas composition, container integrity, and labeling are central. A device-led offering may also require FDA analysis under the medical-device framework if the gas is sold with a proprietary delivery system.

What is the Orange Book status of oxygen-helium mixtures?

A conventional heliox product should not be assumed to have a meaningful Orange Book patent position.

The Orange Book identifies approved drug products and certain patent and exclusivity information. A heliox supplier would need to confirm whether a specific finished product is listed, whether it has an approved application eligible for patent listing, and whether any listed patents cover the product or its use.[5]

The commercial reality is that medical-gas competition generally depends more on:

• Manufacturing authorization
• Distribution infrastructure
• Hospital contracts
• Cylinder fleets
• Regulator compatibility
• Supply reliability
• Device integration
• Clinical protocols

than on Orange Book-listed composition patents.

When does an oxygen-helium mixture lose exclusivity?

There is no universal heliox exclusivity date. Exclusivity depends on the specific sponsor, product, regulatory application, and jurisdiction.

For a standard premixed gas, market entry may be constrained by manufacturing controls, supply contracts, quality specifications, trademarks, equipment compatibility, and local regulatory requirements rather than by a single compound patent expiration date.

U.S. exclusivity and patent timing

Relevant U.S. concepts include:

• New-drug exclusivity, if a qualifying application exists
• Orphan-drug exclusivity, if the product receives orphan designation and approval
• Pediatric exclusivity, if granted
• Method-of-use patents
• Device patents
• Trade secrets covering manufacturing or calibration

A generic manufacturer or competing medical-gas supplier could enter without relying on the same patents if it uses a non-infringing formulation, delivery device, or manufacturing process.

International timing

European, Canadian, Japanese, and other national regimes may classify and regulate medical gases differently. Patent rights are territorial. A U.S. composition or device patent does not establish protection in Europe or Asia. Commercial analysis should separate:

• Product approval rights
• Gas-manufacturing authorization
• Patent rights
• Device clearance
• Hospital tender access
• Cylinder and transport requirements

Are Paragraph IV challenges relevant to heliox?

Paragraph IV litigation is relevant only if a specific heliox product has an FDA-approved application with listed patents in the Orange Book. Standard medical-gas products may not create the same Hatch-Waxman litigation profile as conventional branded drugs.

If listed patents exist, a challenger could assert that the patent is invalid, unenforceable, or not infringed. The main challenge targets would likely be:

• Broad composition claims
• Method-of-use claims
• Device claims incorporated into the product
• Manufacturing claims
• Labeling-based infringement theories

Without an identified reference product and listed patents, no specific Paragraph IV challenger, lawsuit, settlement, or generic-launch date can be assigned.

What generic entry risks exist for heliox?

Generic and competitive-entry risk is high for standard premixed heliox. The product can often be supplied by established medical-gas manufacturers using known oxygen and helium specifications.

Entry barriers remain in several areas:

Barrier	Effect on new entrant
Helium supply	Can increase cost and create supply volatility
Cylinder fleet	Requires capital, testing, maintenance, and reverse logistics
Oxygen-service compliance	Raises safety and quality requirements
Hospital contracts	Slows conversion from incumbent suppliers
Delivery equipment	May lock customers into compatible systems
Clinical adoption	Requires protocols and physician familiarity
Transport regulations	Increase distribution complexity
Margin pressure	Limits returns on undifferentiated gas

The highest risk is price competition in commodity cylinder supply. The lowest substitution risk exists where a supplier owns a clinically integrated delivery system and has secured hospital protocols or long-term contracts.

Which companies are positioned to commercialize oxygen-helium mixtures?

The competitive field includes large industrial-gas companies, regional medical-gas suppliers, hospital gas contractors, respiratory-equipment manufacturers, and specialty distributors.

Relevant competitive capabilities include:

• Medical-gas production
• Helium procurement
• Cylinder filling and testing
• Hospital distribution
• Respiratory-device integration
• Regulatory compliance
• Emergency logistics
• Home respiratory support

Large industrial-gas suppliers have scale and supply-chain advantages. Device manufacturers may have stronger opportunities in integrated systems, especially where heliox is delivered through noninvasive ventilation or high-flow platforms.

What commercial opportunities exist beyond bottled heliox?

The most attractive opportunities are not limited to selling premixed cylinders.

Point-of-care blending

A validated blender could combine oxygen and helium at the bedside and adjust the oxygen fraction according to patient requirements. The system would need accurate sensors, alarm controls, fail-safe oxygen delivery, and validated performance across flow rates.

Portable delivery

Portable cylinders or cartridges could support emergency medical services, transport medicine, ambulances, urgent-care centers, and home use. The principal design constraints are cylinder weight, duration, pressure, regulator performance, and oxygen concentration accuracy.

Integrated respiratory devices

A heliox-compatible ventilator, mask, nebulizer, or high-flow system could capture higher value than the gas alone. Device claims may cover compensation for helium’s effect on flow measurement and automated control of oxygen concentration.

Hospital service contracts

A supplier could sell a managed program covering gas, cylinders, regulators, maintenance, staff training, and emergency replenishment. This model creates recurring revenue and makes substitution more difficult.

Clinical-protocol commercialization

A sponsor could support targeted use in emergency departments, pediatric intensive-care units, transport teams, and airway-obstruction programs. The commercial case would require evidence showing reduced intubation, shorter respiratory support, lower treatment cost, or improved throughput.

How does heliox compare with competing respiratory-support products?

Product	Primary advantage	Main limitation	Commercial position
Heliox	Lower gas density and reduced flow resistance	Limited oxygen content and mixed clinical evidence	Adjunctive specialty therapy
Oxygen alone	Widely available and essential for hypoxemia	Does not reduce gas density	Core hospital product
High-flow nasal oxygen	Delivers heated, humidified gas at high flow	Requires equipment and oxygen capacity	Broad respiratory-support market
Noninvasive ventilation	Provides pressure support	Interface intolerance and monitoring needs	Established hospital platform
Nebulized therapy	Delivers pharmacologic treatment	Does not directly address all airway mechanics	Complementary therapy
Airway intervention	Treats mechanical obstruction directly	Invasive or procedure-dependent	Definitive treatment in selected cases

Heliox is most defensible as an adjunct that buys time, improves treatment delivery, or supports transport. It is less defensible as a broad replacement for oxygen, noninvasive ventilation, or airway intervention.

What revenue exposure and investment risks should be assessed?

Revenue potential depends on utilization rather than unit price. A cylinder-only model is likely to have modest margins unless the supplier controls helium procurement and distribution. An integrated gas-and-device model can increase revenue per patient episode and create recurring service income.

Key diligence metrics include:

• Number of hospitals using heliox
• Annual cylinder consumption
• Average treatment duration
• Helium cost per patient episode
• Cylinder turnaround time
• Gas wastage rate
• Emergency-department utilization
• Device attachment rate
• Hospital contract renewal rate
• Gross margin by gas ratio
• Incidence of supply interruption
• Clinical outcome improvement

The principal investment risks are helium-price volatility, uncertain clinical adoption, limited reimbursement leverage, product commoditization, equipment incompatibility, and weak patent protection for the gas composition.

Key Takeaways

• Oxygen-helium mixture, or heliox, is a binary active-gas product with no conventional excipient.
• The main formulation variables are oxygen-to-helium ratio, purity, moisture, contamination limits, pressure, and delivery accuracy.
• Composition patents are likely weaker than device, monitoring, manufacturing, and clinical-protocol patents.
• Orange Book and Paragraph IV analysis depends on a specific FDA-listed product and patent record.
• Generic-entry risk is high for standard premixed heliox.
• Commercial differentiation is strongest in portable systems, point-of-care blending, respiratory-device integration, and managed hospital supply.
• Helium procurement, cylinder infrastructure, regulatory compliance, and clinical evidence are more important than a traditional excipient strategy.
• The most defensible business model combines validated gas supply with proprietary delivery equipment and clinically supported use protocols.

Frequently Asked Questions

Is helium an excipient in an oxygen-helium medical gas?

No. In heliox, helium is an active therapeutic component because it reduces gas density and can lower airflow resistance.

Can an oxygen-helium mixture contain preservatives?

A conventional heliox product does not require preservatives. The formulation should instead control purity, moisture, particulates, hydrocarbons, and container integrity.

Is heliox a generic drug?

Heliox can face competitive entry from medical-gas suppliers, but the regulatory and commercial pathway does not necessarily follow the conventional generic-tablet model.

Can heliox be delivered through a standard oxygen regulator?

Not automatically. Low-density helium mixtures can affect flow-meter accuracy and regulator performance. The delivery system should be validated for the specific gas composition.

What is the strongest patent strategy for a heliox company?

The strongest strategy is usually a layered portfolio covering gas blending, composition control, delivery hardware, sensor-based monitoring, patient-specific oxygen adjustment, and validated treatment protocols.

References

1. American Association for Respiratory Care. (2002). AARC clinical practice guideline: Application of continuous positive airway pressure to the neonate, infant, and child. Respiratory Care, 47(9), 1023-1029.

2. Cochrane Collaboration. (2013). Heliox for croup in children. Cochrane Database of Systematic Reviews.

3. Papamoschou, D. (1995). Theoretical validation of the respiratory benefits of helium-oxygen mixtures. Respiratory Physiology, 99(1), 183-190.

4. U.S. Food and Drug Administration. (2016). Medical gas regulation: Final rule. Federal Register, 81 Fed. Reg. 81685.

5. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. Center for Drug Evaluation and Research.